Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

3 months ago

Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™…

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

3 months ago

DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the…

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

3 months ago

CHATHAM, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated…

Grow Up Conference & Expo Debuts in Vancouver

3 months ago

B2B cannabis event returns to B.C. for three days of education and business-building Brands & Buyers Zone Connect with retail…

Humber River Health Achieves Excellent Scores, Remarkably Low Rate of Patient Harm, Leading Provincial and National Benchmarks

3 months ago

Humber River Hospital Humber River Health’s hospital harm rates in comparison to the provincial and national averages. Data provided by…

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

3 months ago

Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc.…

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

3 months ago

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…

Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income

3 months ago

Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net…

Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio

3 months ago

World-renowned longevity physician to help guide Klothea Bio as it prepares for a Phase 1B clinical trial of its Klotho…

Genvor Restores Trading Status and Expands Global Collaborative Research Network

3 months ago

Woodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable…